SASKATOON, Saskatchewan — November 28, 2025 — Leads & Copy — PharmaCorp RX Inc. (TSXV: PCRX) has released its financial results for the three and nine months ending Sept. 30, 2025, reporting continued operational momentum and increased financial performance across pharmacy locations.
The company attributes the success to higher revenues, improved margins, better operating efficiencies, and progress in its national acquisition strategy.
Following the end of the quarter, PharmaCorp finalized the acquisition of three pharmacies, including two in Western Canada and one in Eastern Canada. These acquisitions will build scale and reinforce the platform’s coast-to-coast ambitions, the company said.
Q3 2025 Financial Highlights:
- Revenues increased due to higher prescription volumes and front-of-store sales.
- Same-store sales, a supplementary financial measure, increased 9.4% year-over-year compared to Q3 2024, reflecting continued organic growth across our pharmacy network.
- Prescription volumes continue to grow, with total script count rising 7.2% year-over-year compared to Q3 2024, demonstrating sustained patient engagement and activity across the network.
- Operating infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy onboarding, and co-ownership execution.
- The net loss for the quarter reflects continued investment in corporate infrastructure, stock options granted to directors and officers on July 18, 2025, as well as one-time legal fees to obtain credit facility with CIBC.
- Solid pharmacy-level contribution margins and a disciplined weighted average EBITDA multiples across acquisitions support PharmaCorp’s long-term accretive growth model.
Alan Simpson, Executive Chairman of PharmaCorp, said the company is encouraged by the strong performance of its initial acquisitions and by the ongoing interest from independent pharmacy owners considering their succession options.
Simpson said the quarter demonstrates steady progress in scaling the business through disciplined execution, and the company remains committed to maintaining a disciplined weighted average EBITDA multiple across transactions, reinforcing its objective of achieving accretive growth.
During the quarter, PharmaCorp invested in systems, personnel, and integration processes. The reported net loss includes options which were granted to directors and officers on July 18, 2025, and one-time legal fees to obtain credit facility with CIBC.
Subsequent Events:
- On Oct. 2, 2025, PharmaCorp purchased a 100% interest in two pharmacies located in Western Canada, one of which includes the associated land and building. The aggregate purchase price for the 100% interest was $3.4 million, funded from cash and shares.
- Also on Oct. 2, 2025, PharmaCorp purchased a 100% interest in a pharmacy located in Eastern Canada for $5.3 million, funded from cash and available funds under the Corporation’s credit facility.
- On Nov. 12, 2025, PharmaCorp closed its previously announced bought deal public offering co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited, and including Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc. (the “Underwriters”). The Underwriters purchased 54,855,000 units in the capital of the Corporation at C$0.42 per Unit, with aggregate gross proceeds to PharmaCorp of approximately C$23.0 million, including the full exercise of the over-allotment option.
For comprehensive disclosure, refer to PharmaCorp’s unaudited Condensed Consolidated Interim Financial Statements and related Management’s Discussion and Analysis for the three and nine months ended Sept. 30, 2025, filed on SEDAR+ at www.sedarplus.ca.
Alan Simpson, Executive Chairman of PharmaCorp
Investor Relations
info@pharmacorprx.ca
Tel: (306) 536-3771
